MX381332B - Derivados novedosos de pirrolidina. - Google Patents

Derivados novedosos de pirrolidina.

Info

Publication number
MX381332B
MX381332B MX2018009638A MX2018009638A MX381332B MX 381332 B MX381332 B MX 381332B MX 2018009638 A MX2018009638 A MX 2018009638A MX 2018009638 A MX2018009638 A MX 2018009638A MX 381332 B MX381332 B MX 381332B
Authority
MX
Mexico
Prior art keywords
pyrrolidine derivatives
sup
novel pyrrolidine
compound
formula
Prior art date
Application number
MX2018009638A
Other languages
English (en)
Other versions
MX2018009638A (es
Inventor
Bernd Kuhn
Jens-Uwe Peters
Thomas Luebbers
Wolfgang Haap
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2018009638A publication Critical patent/MX2018009638A/es
Publication of MX381332B publication Critical patent/MX381332B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a un compuesto de fórmula (I): (ver Fórmula) en la que R1 y R2 son tal como se define en la descripción y en las reivindicaciones. El compuesto de fórmula (I) puede usarse como medicamento.
MX2018009638A 2016-02-26 2017-02-22 Derivados novedosos de pirrolidina. MX381332B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16157679 2016-02-26
PCT/EP2017/053967 WO2017144483A1 (en) 2016-02-26 2017-02-22 Novel pyrrolidine derivatives

Publications (2)

Publication Number Publication Date
MX2018009638A MX2018009638A (es) 2018-09-11
MX381332B true MX381332B (es) 2025-03-12

Family

ID=55443159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009638A MX381332B (es) 2016-02-26 2017-02-22 Derivados novedosos de pirrolidina.

Country Status (32)

Country Link
US (1) US10689339B2 (es)
EP (1) EP3419970B1 (es)
JP (1) JP6952044B2 (es)
KR (1) KR102797060B1 (es)
CN (1) CN108699044B (es)
AR (1) AR107717A1 (es)
AU (1) AU2017224343B2 (es)
CA (1) CA3011652C (es)
CL (1) CL2018002347A1 (es)
CO (1) CO2018007756A2 (es)
CR (1) CR20180404A (es)
DK (1) DK3419970T3 (es)
ES (1) ES2775781T3 (es)
HR (1) HRP20200307T1 (es)
HU (1) HUE047842T2 (es)
IL (1) IL260130B (es)
LT (1) LT3419970T (es)
MA (1) MA43667B1 (es)
MX (1) MX381332B (es)
MY (1) MY196560A (es)
PE (1) PE20181627A1 (es)
PH (1) PH12018501585B1 (es)
PL (1) PL3419970T3 (es)
PT (1) PT3419970T (es)
RS (1) RS59938B1 (es)
RU (1) RU2736498C1 (es)
SG (1) SG11201807074VA (es)
SI (1) SI3419970T1 (es)
TW (1) TWI740903B (es)
UA (1) UA122084C2 (es)
WO (1) WO2017144483A1 (es)
ZA (1) ZA201804120B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI764976B (zh) 2017-01-24 2022-05-21 日商安斯泰來製藥股份有限公司 取代苯基二氟甲基之脯胺酸醯胺化合物
TWI846731B (zh) * 2018-09-18 2024-07-01 瑞士商赫孚孟拉羅股份公司 組織蛋白酶(cathepsin)S抑制劑之對抗抗藥抗體形成之用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011094A (es) * 2009-04-20 2011-11-04 Hoffmann La Roche Derivados de prolina como inhibidores de catepsina.
AU2012334123B2 (en) * 2011-11-11 2016-12-15 F. Hoffmann-La Roche Ag Process for the preparation of 1-acyl-4-phenylsulfonylprolinamide derivatives and new intermediates
MX2014006211A (es) * 2011-11-25 2014-08-08 Hoffmann La Roche Nuevos derivados de pirrolidina como inhibidores de catepsina.
US9427108B2 (en) * 2011-12-09 2016-08-30 W.C. Bradley Co. Cooking grate with adjustable heating characteristics
CN104114549A (zh) * 2012-02-17 2014-10-22 霍夫曼-拉罗奇有限公司 新型吡咯烷衍生物
SG11201500900YA (en) * 2012-08-21 2015-03-30 Hoffmann La Roche Novel pyridine derivatives

Also Published As

Publication number Publication date
EP3419970A1 (en) 2019-01-02
EP3419970B1 (en) 2020-01-01
WO2017144483A1 (en) 2017-08-31
KR20180111862A (ko) 2018-10-11
CO2018007756A2 (es) 2018-10-10
CA3011652C (en) 2024-01-09
ES2775781T3 (es) 2020-07-28
DK3419970T3 (da) 2020-03-02
CN108699044A (zh) 2018-10-23
SI3419970T1 (sl) 2020-04-30
PH12018501585A1 (en) 2019-04-08
AU2017224343A1 (en) 2018-07-05
PH12018501585B1 (en) 2021-03-31
UA122084C2 (uk) 2020-09-10
CR20180404A (es) 2018-10-18
CN108699044B (zh) 2022-03-04
IL260130B (en) 2020-08-31
AU2017224343B2 (en) 2020-09-10
TWI740903B (zh) 2021-10-01
MA43667B1 (fr) 2020-03-31
PE20181627A1 (es) 2018-10-11
JP6952044B2 (ja) 2021-10-20
JP2019506416A (ja) 2019-03-07
RU2736498C1 (ru) 2020-11-17
PT3419970T (pt) 2020-02-28
RS59938B1 (sr) 2020-03-31
KR102797060B1 (ko) 2025-04-18
ZA201804120B (en) 2020-07-29
PL3419970T3 (pl) 2020-06-01
IL260130A (en) 2018-07-31
CA3011652A1 (en) 2017-08-31
TW201733981A (zh) 2017-10-01
HUE047842T2 (hu) 2020-05-28
MX2018009638A (es) 2018-09-11
AR107717A1 (es) 2018-05-23
SG11201807074VA (en) 2018-09-27
HRP20200307T1 (hr) 2020-06-12
LT3419970T (lt) 2020-03-10
CL2018002347A1 (es) 2018-11-30
US10689339B2 (en) 2020-06-23
US20180362461A1 (en) 2018-12-20
MY196560A (en) 2023-04-19

Similar Documents

Publication Publication Date Title
JOP20200011A1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
MX381417B (es) Inhibidores de glucosidasa.
GEAP202115066A (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
UA118666C2 (uk) Похідні піразолу
PH12015501933A1 (en) Novel pyridine derivatives
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
BR112015018504A2 (pt) moduladores de flap
PH12018501181A1 (en) Phenyl derivatives as cannabinoid receptor 2 agonists
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
MX2019010085A (es) Inhibidores de la glicosidasa de sulfoximina.
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
EA201692270A1 (ru) Производные нафтиридиндиона
MX383577B (es) Derivados sustituidos de guanidina.
GEP20186893B (en) Pyrazines modulators of gpr6
JOP20240127A1 (ar) مركبات ثنائي آزا سبيرو بها استبدال بكربونيل واستخدامها
BR112015029691A2 (pt) novos compostos 3,4-dihidro-2h-isoquinolina-ona e 2,3-dihidro-isoindol-1-ona
MX2015016766A (es) Nuevos derivados de tetrazolona.
PH12018501585A1 (en) Novel pyrrolidine derivatives
WO2015181837A3 (en) Novel compounds as anti-tubercular agents